Results 51 to 60 of about 129,216 (298)

The acceleration of metastases after tumor removal and the paradoxical phenomenon of concomitant tumor resistance [PDF]

, 2018
Although surgical extirpation of tumors is usually clinically recommended, tumor removal may entail an undesired side effect: the risk of accelerating the growth of metastases.
Chiarella, Paula, Meiss, Roberto P., Montagna, Daniela Romina, Ruggiero, Raul Alejandro   +3 more
core   +1 more source

Decoding immunogenic cell death from a dendritic cell perspective

Immunological Reviews, 2023
SummaryDendritic cells (DCs) are myeloid cells bridging the innate and adaptive immune system. By cross‐presenting tumor‐associated antigens (TAAs) liberated upon spontaneous or therapy‐induced tumor cell death to T cells, DCs occupy a pivotal position in the cancer immunity cycle.
Janssens, Sophie, Rennen, Sofie, Agostinis, Patrizia   +2 more
openaire   +2 more sources

Molecular mechanisms of cell death:recommendations of the Nomenclature Committee on Cell Death 2018 [PDF]

, 2018
Over the past decade, the Nomenclature Committee on Cell Death (NCCD) has formulated guidelines for the definition and interpretation of cell death from morphological, biochemical, and functional perspectives.
Aaronson, Stuart A., Abrams, John M., Adam, Dieter, Agostinis, Patrizia, Alnemri, Emad S., Altucci, Lucia, Amelio, Ivano, Andrews, David W., Annicchiarico-Petruzzelli, Margherita, Antonov, Alexey V., Arama, Eli, Baehrecke, Eric H., Barlev, Nickolai A., Bazan, Nicolas G., Bernassola, Francesca, Bertrand, Mathieu J. M., Bianchi, Katiuscia, Blagosklonny, Mikhail V., Blomgren, Klas, Borner, Christoph, Boya, Patricia, Brenner, Catherine, Campanella, Michelangelo, Candi, Eleonora, Carmona-Gutierrez, Didac, Cecconi, Francesco, Chan, Francis K. -M., Chandel, Navdeep S., Cheng, Emily H., Chipuk, Jerry E., Cidlowski, John A., Ciechanover, Aaron, Cohen, Gerald M., Conrad, Marcus, Cubillos-Ruiz, Juan R., Czabotar, Peter E., D'Angiolella, Vincenzo, Dawson, Ted M., Dawson, Valina L., De laurenzi, Vincenzo, De Maria, Ruggero, Debatin, Klaus-Michael, DeBerardinis, Ralph J., Deshmukh, Mohanish, Di Daniele, Nicola, Di Virgilio, Francesco, Dixit, Vishva M., Dixon, Scott J., Duckett, Colin S., Dynlacht, Brian D., El-Deiry, Wafik S., Elrod, John W., Fimia, Gian Maria, Fulda, Simone, Galluzzi, Lorenzo, Garcia-Saez, Ana J., Garg, Abhishek D., Garrido, Carmen, Gavathiotis, Evripidis, Golstein, Pierre, Gottlieb, Eyal, Green, Douglas R., Greene, Lloyd A., Gronemeyer, Hinrich, Gross, Atan, Hajnoczky, Gyorgy, Hardwick, J. Marie, Harris, Isaac S., Heiden, Matthew G. Vander, Hengartner, Michael O., Hetz, Claudio, Ichijo, Hidenori, Jaattela, Marja, Joseph, Bertrand, Jost, Philipp J., Juin, Philippe P., Kaiser, William J., Karin, Michael, Kaufmann, Thomas, Kepp, Oliver, Kimchi, Adi, Kitsis, Richard N., Klionsky, Daniel J., Knight, Richard A., Kroemer, Guido, Kumar, Sharad, Lee, Sam W., Lemasters, John J., Levine, Beth, Linkermann, Andreas, Lipton, Stuart A., Lockshin, Richard A., Lopez-Otin, Carlos, Lowe, Scott W., Luedde, Tom, Lugli, Enrico, MacFarlane, Marion, Madeo, Frank, Malewicz, Michal, Malorni, Walter, Manic, Gwenola, Marine, Jean-Christophe, Martin, Seamus J., Martinou, Jean-Claude, Medema, Jan Paul, Mehlen, Patrick, Meier, Pascal, Melino, Gerry, Melino, Sonia, Miao, Edward A., Molkentin, Jeffery D., Moll, Ute M., Munoz-Pinedo, Cristina, Nagata, Shigekazu, Nunez, Gabriel, Oberst, Andrew, Oren, Moshe, Overholtzer, Michael, Pagano, Michele, Panaretakis, Theocharis, Pasparakis, Manolis, Penninger, Josef M., Pereira, David M., Pervaiz, Shazib, Peter, Marcus E., Piacentini, Mauro, Pinton, Paolo, Prehn, Jochen H. M., Puthalakath, Hamsa, Rabinovich, Gabriel A., Rehm, Markus, Rizzuto, Rosario, Rodrigues, Cecilia M. P., Rubinsztein, David C., Rudel, Thomas, Ryan, Kevin M., Sayan, Emre, Scorrano, Luca, Shao, Feng, Shi, Yufang, Silke, John, Simon, Hans-Uwe, Sistigu, Antonella, Stockwell, Brent R., Strasser, Andreas, Szabadkai, Gyorgy, Tait, Stephen W. G., Tang, Daolin, Tavernarakis, Nektarios, Thorburn, Andrew, Tsujimoto, Yoshihide, Turk, Boris, Vanden Berghe, Tom, Vandenabeele, Peter, Villunger, Andreas, Virgin, Herbert W., Vitale, Ilio, Vousden, Karen H., Vucic, Domagoj, Wagner, Erwin F., Walczak, Henning, Wallach, David, Wang, Ying, Wells, James A., Wood, Will, Yuan, Junying, Zakeri, Zahra, Zhivotovsky, Boris, Zitvogel, Laurence   +168 more
core   +25 more sources

Mathematical Models of Death Signaling Networks

Entropy, 2022
This review provides an overview of the progress made by computational and systems biologists in characterizing different cell death regulatory mechanisms that constitute the cell death network.
Madhumita Srinivasan, Robert Clarke, Pavel Kraikivski   +2 more
doaj   +1 more source

Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors [PDF]

, 2019
Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR), and both are widely used in combination with chemotherapy or as monotherapy to treat patients with RAS wild-type metastatic ...
Aderka, Dan, García Foncillas, Jesús, Ronga, Philippe, Stintzing, Sebastian, Sunakawa, Yu, Wainberg, Zev, Witzler, Pauline   +6 more
core   +1 more source

Screening for immunogenic cell death [PDF]

Science-Business eXchange, 2012
French researchers have used a fluorescence-based screening platform to identify small molecules that induced immunogenic cell death in mouse tumors. Next, the group plans to test the best hits in a Phase I/II trial to treat locally invasive head and neck cancers in combination with chemotherapy.
openaire   +1 more source

Trial Watch [PDF]

OncoImmunology, 2013
Accumulating evidence suggests that the clinical efficacy of selected anticancer drugs, including conventional chemotherapeutics as well as targeted anticancer agents, originates (at least in part) from their ability to elicit a novel or reinstate a pre-existing tumor-specific immune response.
Vacchelli, Erika, Aranda, Fernando, Eggermont, Alexander, Galon, Jérôme, Sautès-Fridman, Catherine, Cremer, Isabelle, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo   +8 more
openaire   +4 more sources

Immunogenic Cell Death Role in Urothelial Cancer Therapy

Current Oncology, 2022
Purpose: Bladder cancer is the 13th most common cause of cancer death with the highest lifetime cost for treatment of all cancers. This scoping review clarifies the available evidence on the role of a novel therapeutic approach called immunogenic cell ...
Reza Yadollahvandmiandoab, Mehrsa Jalalizadeh, Keini Buosi, Herney Andrés Garcia-Perdomo, Leonardo Oliveira Reis   +4 more
doaj   +1 more source

Escape from immunotherapy: possible mechanisms that influence tumor regression/progression [PDF]

, 2004
Tumor escape is one major obstacle that has to be addressed prior to designing and delivering successful immunotherapy. There is compelling evidence to support the notion that immunogenic tumors, in murine models and cancer patients, can be rejected by ...
Ahmad, M, Ali, SA, Rees, RC
core   +1 more source

Immunogenic cell death inducers as anticancer agents

Oncotarget, 2014
It has been widely thought that the occasional success of anticancer chemotherapies is mediated by direct, efficient cytostatic or (better) cytotoxic effects of the antineoplastic agent on tumor cells. Nonetheless, there is accumulating evidence for the hypothesis that long-term clinical success (which is measured in years and decades rather than weeks
Oliver, Kepp, Laura, Senovilla, Guido, Kroemer   +2 more
openaire   +2 more sources